Hemostemix (CVE:HEM) Shares Down 20% – What’s Next?

Hemostemix Inc. (CVE:HEM – Get Free Report) fell 20% during mid-day trading on Monday. The stock traded as low as C$0.04 and last traded at C$0.04. 145,275 shares changed hands during mid-day trading, an increase of 236% from the average daily volume of 43,224 shares. The stock had previously closed at C$0.05.

Hemostemix Trading Down 14.3%

The company has a market cap of C$6.34 million, a P/E ratio of -1.15 and a beta of -0.14. The company has a quick ratio of 0.48, a current ratio of 0.13 and a debt-to-equity ratio of -61.85. The firm’s 50-day moving average price is C$0.06 and its 200-day moving average price is C$0.07.

About Hemostemix

(Get Free Report)

Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.

Featured Articles

Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.